The reimbursement is received for desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor
The 4 P-II efficacy and safety study of imlifidase was conducted as a pre-transplant treatment to reduce donor-specific IgG and plans to submit additional efficacy and safety data based on one observational follow-up study and one post-approval efficacy study
Imlifidase, an enzyme derived from the bacterium Streptococcus pyogenes having ability to cleave with IgG and inactivate high levels of antibodies (anti-HLA) in highly sensitized patients to protect them from the binding to the donor organ and damage the transplant that increases the opportunity of transplantation
Ref: PR Newswire | Image: Hansa
Related News:- Hansa Biopharma’s Idefirix (imlifidase) Receives NICE Recommendation as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
